

CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 14.02.2019

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai -400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.02.2019

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Thursday, 14.02.2019 at 5:00 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayatnagar Mandal - 501511, Telangana, the Un - Audited financial results for the quarter ended 31.12.2018 along with Limited Review Report was considered and approved.

The meeting concluded at 6.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited



S. Nagi Reddy
Chairman and whole-time Director
DIN: 01764665

Encl: as above

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st December 2018

[Rs. in Lakhs]

Particulars	Quarterly ended			Nine Months Ended		Year ended
	31-Dec-18	30-Sep-18	31-Dec-17	April 2018 to Dec 2018	April 2017 to Dec 2017	31-Mar-18
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from Operations						
a. Net sales from Operations	921.00	1,149.10	596.12	3,373.27	3,070.17	5,179.72
b. Other Operating Income	-	-	-	-	-	-
II Other Income	1.90	1.90	1.21	6.43	2.19	13.58
III Total Revenue (I+II)	922.90	1,151.00	597.33	3,379.70	3,072.36	5,193.31
IV Expenses						
a. Cost of Material Consumed	625.37	760.96	262.15	2,570.92	2,629.71	4,650.17
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	22.85	164.69	45.07	96.32	433.71	320.38
c. Employees Benefit Expenses	81.59	84.46	74.19	218.77	213.58	197.42
d. Finance Costs	39.90	38.95	43.41	120.32	131.24	188.40
e. Depreciation and Amortisation expense	54.86	54.81	59.67	163.83	171.96	240.14
f. Other expenses	92.78	42.20	152.13	191.95	294.25	173.68
Total Expenses	917.35	1,146.07	546.48	3,362.11	3,007.03	5,129.44
Profit/ (Loss) before Exceptional item and tax (III-IV)	5.55	4.93	50.85	17.59	65.32	63.87
V Exceptional Items						
VI Profit/ (Loss) before tax (V-VI)	5.55	4.93	50.85	17.59	65.32	63.87
VII Tax Expense:	1.87	1.20	15.22	(2.59)	19.60	31.45
VIII Current tax	4.84	8.92	15.22	15.22	19.60	37.58
Deferred tax charge/credit	2.97	7.72	-	17.80	-	6.13
MAT Credit	-	-	-	-	-	-
IX Profit/ (Loss) for the period (VII-VIII)	3.68	3.73	35.63	20.18	45.73	32.42
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss						
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	3.68	3.73	35.63	20.18	45.73	32.42
XI Paid-up equity share capital	786.18	786.18	786.18	786.18	786.18	786.18
Face value of the share- Rs. 10 each)						
Other Equity	114.29	114.29				1,146.14
XII Earnings per share (of Rs. 10 each)						
XIII Basic (in Rs)	0.05	0.05	0.45	0.26	0.58	0.41
Diluted (in Rs)	0.05	0.05	0.41	0.25	0.52	0.41

Notes:

- Financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) Prescribed under section 133 of the Companies Act, 2013.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14-02-2019.
- The company operates in only one Segment viz., "Pharmaceutical Products".
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period.

For CONCORD DRUGS LIMITED

S. N. Srinivas

Chairman

Place: Hyderabad
Date: 14-02-2019



**Limited review Report on Quarterly unaudited standalone financial results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To
Board of Directors of
M/s. Concord Drugs Limited.


We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Concord Drugs Ltd ("the Company") for the quarter ended 31-12-2018, and year-to-date results for the period from 01 April, 2018 to 31 December 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the company in their meeting held on 14-02-2019. Our responsibility is to issue a report on these financial statements

We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, 'Review of Interim Financial Statements performed by the Independent Auditor of the Entity' specified u/s 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e., IndAS prescribed under section 133 of the Act and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G RAO & ASSOCIATES
Chartered Accountants
FRNo.009399S



Partner: G Nageshwara Rao
Membership No.207300
Place: Hyderabad
Date: 14-02-2019.